Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
Conclusions The clinical benefit parameters of Lipo-MIT and MIT were comparable. Lipo-MIT provided a different toxicity profile, which might be associated with the altered distribution of the drug. Additional study is needed to elucidate the potential benefit of Lipo-MIT in ABC.Clinical trial registration. This study is registered with ClinicalTrials.gov (No. NCT02596373) on Nov 4, 2015.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | China Health | Clinical Trials | Drugs & Pharmacology | Heart | Investigational New Drugs | Skin | Study | Toxicology